FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136239231> ?p ?o ?g. }

• W3136239231 abstract "Ipilimumab has shown long-term overall survival (OS) in patients with advanced melanoma in clinical trials, but robust real-world evidence is lacking. We present long-term outcomes from the IMAGE study (NCT01511913) in patients receiving ipilimumab and/or non-ipilimumab (any approved treatment other than ipilimumab) systemic therapies.IMAGE was a multinational, prospective, observational study assessing adult patients with advanced melanoma treated with ipilimumab or non-ipilimumab systemic therapies between June 2012 and March 2015 with ≥3 years of follow-up. Adjusted OS curves based on multivariate Cox regression models included covariate effects. Safety and patient-reported outcomes were assessed.Among 1356 patients, 1094 (81%) received ipilimumab and 262 (19%) received non-ipilimumab index therapy (systemic therapy [chemotherapy, anti-programmed death 1 antibodies, or BRAF ± MEK inhibitors], radiotherapy, and radiosurgery). In the overall population, median age was 64 years, 60% were male, 78% were from Europe, and 78% had received previous treatment for advanced melanoma. In the ipilimumab-treated cohort, 780 (71%) patients did not receive subsequent therapy (IPI-noOther) and 314 (29%) received subsequent non-ipilimumab therapy (IPI-Other) on study. In the non-ipilimumab-treated cohort, 205 (78%) patients remained on or received other subsequent non-ipilimumab therapy (Other-Other) and 57 (22%) received subsequent ipilimumab therapy (Other-IPI) on study. Among 1151 patients who received ipilimumab at any time during the study (IPI-noOther, IPI-Other, and Other-IPI), 296 (26%) reported CTCAE grade ≥ 3 treatment-related adverse events, most occurring in year 1. Ipilimumab-treated and non-ipilimumab-treated patients who switched therapy (IPI-Other and Other-IPI) had longer OS than those who did not switch (IPI-noOther and Other-Other). Patients with prior therapy who did not switch therapy (IPI-noOther and Other-Other) showed similar OS. In treatment-naive patients, those in the IPI-noOther group tended to have longer OS than those in the Other-Other group. Patient-reported outcomes were similar between treatment cohorts.With long-term follow-up (≥ 3 years), safety and OS in this real-world population of patients treated with ipilimumab 3 mg/kg were consistent with those reported in clinical trials. Patient-reported quality of life was maintained over the study period. OS analysis across both pretreated and treatment-naive patients suggested a beneficial role of ipilimumab early in treatment.ClinicalTrials.gov , NCT01511913. Registered January 19, 2012 - Retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT01511913." @default.
• W3136239231 created "2021-03-29" @default.
• W3136239231 creator A5002050944 @default.
• W3136239231 creator A5002579123 @default.
• W3136239231 creator A5004458225 @default.
• W3136239231 creator A5009056091 @default.
• W3136239231 creator A5014374360 @default.
• W3136239231 creator A5015081105 @default.
• W3136239231 creator A5021108238 @default.
• W3136239231 creator A5026331025 @default.
• W3136239231 creator A5035574764 @default.
• W3136239231 creator A5044515899 @default.
• W3136239231 creator A5051430596 @default.
• W3136239231 creator A5059674386 @default.
• W3136239231 creator A5059918466 @default.
• W3136239231 creator A5073133195 @default.
• W3136239231 creator A5074296844 @default.
• W3136239231 creator A5077284234 @default.
• W3136239231 creator A5077421764 @default.
• W3136239231 creator A5079727866 @default.
• W3136239231 creator A5089274878 @default.
• W3136239231 date "2021-05-29" @default.
• W3136239231 modified "2023-10-04" @default.
• W3136239231 title "Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study" @default.
• W3136239231 cites W1947168884 @default.
• W3136239231 cites W2097995306 @default.
• W3136239231 cites W2114649921 @default.
• W3136239231 cites W2121071739 @default.
• W3136239231 cites W2123363005 @default.
• W3136239231 cites W2133075384 @default.
• W3136239231 cites W2164281389 @default.
• W3136239231 cites W2166667372 @default.
• W3136239231 cites W2167571044 @default.
• W3136239231 cites W2338981437 @default.
• W3136239231 cites W2344830850 @default.
• W3136239231 cites W2400472415 @default.
• W3136239231 cites W2588698239 @default.
• W3136239231 cites W2603690292 @default.
• W3136239231 cites W2726861941 @default.
• W3136239231 cites W2747107882 @default.
• W3136239231 cites W2793018924 @default.
• W3136239231 cites W2898510820 @default.
• W3136239231 cites W2911188335 @default.
• W3136239231 cites W2956028371 @default.
• W3136239231 cites W2965528879 @default.
• W3136239231 cites W3035324474 @default.
• W3136239231 cites W3043703771 @default.
• W3136239231 cites W3090469545 @default.
• W3136239231 cites W3118520330 @default.
• W3136239231 cites W2981716524 @default.
• W3136239231 doi "https://doi.org/10.1186/s12885-021-08032-y" @default.
• W3136239231 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8164785" @default.
• W3136239231 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34051732" @default.
• W3136239231 hasPublicationYear "2021" @default.
• W3136239231 type Work @default.
• W3136239231 sameAs 3136239231 @default.
• W3136239231 citedByCount "7" @default.
• W3136239231 countsByYear W31362392312022 @default.
• W3136239231 countsByYear W31362392312023 @default.
• W3136239231 crossrefType "journal-article" @default.
• W3136239231 hasAuthorship W3136239231A5002050944 @default.
• W3136239231 hasAuthorship W3136239231A5002579123 @default.
• W3136239231 hasAuthorship W3136239231A5004458225 @default.
• W3136239231 hasAuthorship W3136239231A5009056091 @default.
• W3136239231 hasAuthorship W3136239231A5014374360 @default.
• W3136239231 hasAuthorship W3136239231A5015081105 @default.
• W3136239231 hasAuthorship W3136239231A5021108238 @default.
• W3136239231 hasAuthorship W3136239231A5026331025 @default.
• W3136239231 hasAuthorship W3136239231A5035574764 @default.
• W3136239231 hasAuthorship W3136239231A5044515899 @default.
• W3136239231 hasAuthorship W3136239231A5051430596 @default.
• W3136239231 hasAuthorship W3136239231A5059674386 @default.
• W3136239231 hasAuthorship W3136239231A5059918466 @default.
• W3136239231 hasAuthorship W3136239231A5073133195 @default.
• W3136239231 hasAuthorship W3136239231A5074296844 @default.
• W3136239231 hasAuthorship W3136239231A5077284234 @default.
• W3136239231 hasAuthorship W3136239231A5077421764 @default.
• W3136239231 hasAuthorship W3136239231A5079727866 @default.
• W3136239231 hasAuthorship W3136239231A5089274878 @default.
• W3136239231 hasBestOaLocation W31362392311 @default.
• W3136239231 hasConcept C121608353 @default.
• W3136239231 hasConcept C126322002 @default.
• W3136239231 hasConcept C143998085 @default.
• W3136239231 hasConcept C197934379 @default.
• W3136239231 hasConcept C2777658100 @default.
• W3136239231 hasConcept C2777701055 @default.
• W3136239231 hasConcept C2781433595 @default.
• W3136239231 hasConcept C2908647359 @default.
• W3136239231 hasConcept C502942594 @default.
• W3136239231 hasConcept C535046627 @default.
• W3136239231 hasConcept C71924100 @default.
• W3136239231 hasConcept C99454951 @default.
• W3136239231 hasConceptScore W3136239231C121608353 @default.
• W3136239231 hasConceptScore W3136239231C126322002 @default.
• W3136239231 hasConceptScore W3136239231C143998085 @default.
• W3136239231 hasConceptScore W3136239231C197934379 @default.
• W3136239231 hasConceptScore W3136239231C2777658100 @default.
• W3136239231 hasConceptScore W3136239231C2777701055 @default.
• W3136239231 hasConceptScore W3136239231C2781433595 @default.
• W3136239231 hasConceptScore W3136239231C2908647359 @default.

• next